GeneGo Extends Agreement with Merck & Co.
News Jun 04, 2008
GeneGo, Inc. has announced that Merck & Co., Inc. has extended its global enterprise agreement. This agreement provides Merck with access to GeneGo's content through MetaBase which includes access to MetaCore and MetaDrug content and GeneGo's internal database of disease biomarkers.
"Effective use of powerful systems biology data mining & analysis solutions have become an essential component of modern day drug discovery and development," said Julie Bryant, VP business development.
"Merck is one of our first customers and we are pleased that they have chosen to renew and extend their agreement."
2nd International Conference on Pharmaceutical Research & Innovations in Pharma Industry
May 30 - May 31, 2019